For a small New Zealand skincare company, research and development has really paid off.
First, Snowberry founder Soraya Hendesi had Auckland University School of Pharmacy scientists test her copper peptide serum to see if the “messenger” role of peptides in the production of collagen could improve ageing skin. Then the Auckland-based company submitted its “Cu-pep” cream to a double-blind, independent clinical trial in Germany.
Hendesi says the research was a gamble, but her faith in the product was rewarded: the serum outperformed the placebo by more than 55% and a successful, niacinbased American skin product called Strivectin by more than 30%.
The results earned Snowberry an invitation to present its findings at the World Congress of Dermatology – a rare honour for an over-thecounter skincare range. It also put it on the radar of a multinational manufacturer, which has picked up the 12-year-old company and has plans to take it global.